Dr Jayant Khandare receives prestigious Dr A V Ramarao Entrepreneurship Award

the dr. Jayant Khandare, Chief Science Officer at Actorius Innovations and Research

CLOSE, November 18, 2022 (GPN): Dr Jayant Khandare, Chief Scientific Officer at Actorius Innovations and Research, was awarded the Dr AV Ramarao Entrepreneurship Award from the National Chemical Laboratory (NCL), Pune.

Dr Jayant Khandare is an academician and technology entrepreneur with extensive experience in developing innovations and technologies in the fields of biotechnology, medical diagnostics and pharmaceutical sciences. He has a prolific scientific publication record with more than 70 peer-reviewed publications, 15 US patents, multiple book chapters and numerous invited lectures.

Also Read :  Stock Market Rally Tumbles As Fed's Powell Hints At Slower Hikes, But Higher Peak Rate

Dr Khandare is a recipient of the Alexander von Humboldt Experienced Researcher fellowship, Germany, the Early Career Scientist award from the Royal Society of Chemistry (RSC), a Fellow of the Royal Society of Chemistry UK (FRSC) and a Fellow of the Maharashtra Academy of Science (MASc) and Director – School of Consciousness, MIT WPU, Pune and co-founder of biotech startups

to develop innovations in the field of cancer diagnostics and therapy.

Dr. Khandare is also the Co-Founder of Actorius Innovations and Research Pvt Ltd (AIR), a Pune-based research and development company that has created novel biomaterials with critical applications in the field of life science, drug delivery and medical diagnostics.

Also Read :  Market Rally Buckling From Fed, Apple, Tesla, Cloud Stocks; What To Do Now

The company launched its first product, the ‘OncoDiscover Liquid Biopsy Test’, a minimally invasive test that can be performed multiple times and requires only 1.5ml of blood volume. This test is a great tool for monitoring therapy and can be done at multiple time points such as during the initial checkup, pre-surgery, post-surgery, post-chemotherapy and during follow-up. Since this test enumerates (counts) the Total Tumor Cells (CTC) present in the patient’s blood, it becomes a quantitative benchmark for monitoring disease progression and the effectiveness of therapy.

Also Read :  Dow Jones Futures: Microsoft, Google Fall On Earnings; Market Rally Runs Up To Key Test

Further developing this technology, Dr Jayant Khandare said, “Using advanced biomaterials, we identify cancer cells from more than a billion cells in that sample. We took ethical clearance from Tata Memorial Hospital, Mumbai to conduct clinical trials. The biomaterial and specificity required for this type of testing is very high and we have succeeded in achieving it.” end

About the Author

Sachin Murdeshwar

Sachin Murdeshwar is a Sr. Journalist and Columnist in several Mainline Newspapers and Portals. He is an avid traveler and enjoys exploring destinations to the core.

Source

Leave a Reply

Your email address will not be published.

Related Articles

Back to top button